Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
IPO Year: 2018
Exchange: NASDAQ
Website: guardanthealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $36.00 | Neutral → Buy | Guggenheim |
| 6/3/2024 | $32.00 | Buy | Jefferies |
| 4/24/2024 | $28.00 | Buy | Craig Hallum |
| 12/14/2023 | Neutral | Guggenheim | |
| 12/13/2023 | Peer Perform | Wolfe Research | |
| 11/13/2023 | $27.00 | Mkt Perform → Outperform | Raymond James |
| 9/28/2023 | $34.00 | Outperform | Bernstein |
| 9/27/2023 | $40.00 | Neutral → Overweight | Piper Sandler |
| 7/5/2023 | $65.00 | Overweight | JP Morgan |
| 5/26/2023 | $28.00 → $40.00 | Neutral → Buy | Citigroup |
144 - Guardant Health, Inc. (0001576280) (Subject)
10-Q - Guardant Health, Inc. (0001576280) (Filer)
8-K - Guardant Health, Inc. (0001576280) (Filer)
8-K - Guardant Health, Inc. (0001576280) (Filer)
8-K - Guardant Health, Inc. (0001576280) (Filer)
424B5 - Guardant Health, Inc. (0001576280) (Filer)
10-Q - Guardant Health, Inc. (0001576280) (Filer)
8-K - Guardant Health, Inc. (0001576280) (Filer)
8-K - Guardant Health, Inc. (0001576280) (Filer)
8-K - Guardant Health, Inc. (0001576280) (Filer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
Guggenheim upgraded Guardant Health from Neutral to Buy and set a new price target of $36.00
Jefferies resumed coverage of Guardant Health with a rating of Buy and set a new price target of $32.00
Craig Hallum resumed coverage of Guardant Health with a rating of Buy and set a new price target of $28.00
Guggenheim initiated coverage of Guardant Health with a rating of Neutral
Wolfe Research initiated coverage of Guardant Health with a rating of Peer Perform
Raymond James upgraded Guardant Health from Mkt Perform to Outperform and set a new price target of $27.00
Bernstein initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $34.00
Piper Sandler upgraded Guardant Health from Neutral to Overweight and set a new price target of $40.00
JP Morgan resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $65.00
Citigroup upgraded Guardant Health from Neutral to Buy and set a new price target of $40.00 from $28.00 previously
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 50,349 shares of its common stock to three new non-executive employees with a grant date of November 8, 2024 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs and stock options were granted as inducements material to the employees entering into employmen
Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excluding Shield) and 10,500 biopharma tests in the third quarter of 2024, representing increases of 21% and 40%, respectively, over the third quarter of 2023 Achieved Guardant360 ASP of over $3,000 Rai
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. ● Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA Fireside chat on Tuesday, November 12 at 10:30 a.m. Eastern Time ● Wolfe Healthcare Conference in New York, NY Hosting 1x1 meetings on Tuesday, November 19 ● Jefferies London Healthcare Conference 2024 in London, UK Presentation on Wednesday, November 20 at 7:30 a.m. Greenwich Mean Time ● Piper Sandler Healthcare Conference
Shield™, the first FDA-approved, Medicare-reimbursed colorectal cancer screening blood test, named to the Medical Care list Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME's annual list of the Best Inventions, which features 200 extraordinary innovations changing lives. To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as health care, AI, and green energy. TIME then evaluated each contender on a number of key factors
Less than half of patients who underwent stool-based CRC screening completed recommended repeat testing Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening adherence at the American College of Gastroenterology (ACG) 2024 Annual Meeting in Philadelphia, Oct. 25-30, 2024. Guardant and its research partners will share real-world data demonstrating poor patient compliance with repeat stool-based screening. A study of more than 350,000 patients shows that less than half of patients who under
Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, G
In study of more than 4,000 patients with advanced gastrointestinal tumors, 24% were able to receive targeted treatment based on genomic profiling results from blood test Study findings are expected to advance liquid biopsy-guided cancer treatment to help improve outcomes for more patients Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the peer-reviewed journal Nature Medicine published results from the SCRUM-Japan GOZILA study confirming that selecting targeted therapy on the basis of Guardant360® CDx liquid biopsy results may significantly extend survival for patients with advanced cancer. The study, led by a research group out of National C
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, an
Leading Italian Hospital System To Offer Proprietary Guardant360® CDx Liquid Biopsy Testing for Therapy Selection in Advanced Cancer Patients Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS ("Policlinico Gemelli") to establish an in-house liquid biopsy testing service as a part of its diagnostics services within its hospital system. Leveraging Guardant Health's cutting-edge proprietary digital sequencing platform, this initiative will include on-site analysis of Guardant360® CDx liquid biopsy tests directly within the Policlinico Gemelli facilities in Rome, Italy. This pr
SC 13G - Guardant Health, Inc. (0001576280) (Subject)
SC 13G - Guardant Health, Inc. (0001576280) (Subject)
SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)
SC 13G - Guardant Health, Inc. (0001576280) (Subject)
SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)
SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)
SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)
SC 13G - Guardant Health, Inc. (0001576280) (Subject)
SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)
SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)
On Thursday, Cathie Wood’s Ark Invest made a significant move by reducing its stake in Tesla Inc (NASDAQ:TSLA), despite a recent bullish outlook on the company’s potential in the autonomous taxi sector. The Tesla Trade The ARK Next Generation Internet ETF (NYSE:ARKW) sold 32,199 shares of Tesla, valued at approximately $8.02 million based on the closing price of $249.23 on the same day. This move comes after recent comments by Wood, who expressed her belief that Tesla’s stock could see a significant surge as it moves into the autonomous taxi business. Wood, in a recent Tiger Money podcast, stated that Tesla could potentially capture up to 50% of the autonomous taxi market, presentin
B of A Securities analyst Michael Ryskin maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $28 to $40.
In the latest quarter, 7 analysts provided ratings for Guardant Health (NASDAQ:GH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 1 0 0 0 3M Ago 2 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $34.29, a high estimate of $44.00, and a low estimate of $28.00. This current average represents a 6.69% decrease from the previous average pri
Goldman Sachs analyst Matthew Sykes maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $28 to $32.
In the last three months, 7 analysts have published ratings on Guardant Health (NASDAQ:GH), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 2 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.71, with a high estimate of $44.00 and a low estimate of $28.00. Highlighting a 1
Guggenheim analyst Subbu Nambi upgrades Guardant Health (NASDAQ:GH) from Neutral to Buy and announces $36 price target.
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $30 to $38.
Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genesOperational improvements streamline workflow and shorten time to resultsUpgraded test covered by Medicare for comprehensive genomic profiling of all advanced solid tumorsGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498. These genes, or cancer biomarkers, enable oncologists to identify the targeted therapies or treatment strategies that are most effective for patients with advanced cancer. In addition t
For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C
For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap
For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry
Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look
Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. "Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "His extensive experience in precision oncology and his commitment to advancing oncology care make him an invaluable addition to our board." A
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company's chief people officer, effective immediately. In the newly-created role, Monroe will lead the human resources function, including people operations; cultural and organizational transformation; talent acquisition; and diversity and inclusion initiatives. Amelia Merrill, who previously served as senior vice president of people, is transitioning to an advisory role with the company. "Terilyn brings deep expertise in leading, transforming, and scaling the human resources function at rapidly growing companies, and we welcome her leadership as we pursu
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world's leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005656/en/Musa Tariq, Chief Marketing Officer of GoFundMe, is joining the Guardant Health board of directors. (Photo: Business Wire) "We are very pleased to welcome Musa Tariq to our board of directors," said Helmy Eltoukhy, Guardan
Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment Study demonstrates need to identify C797X-driven resistance and tailor therapy options appropriately for patients with EGFR-mutant NSCLC Guardant Health Inc. (NASDAQ:GH), a leading precision oncology company, and Blueprint Medicines Corporation (NASDAQ:BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results ar
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Steve E. Krognes to its board of directors. Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Gritstone bio, Inc. and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc. "We are very pleased to welcome Steve Krognes to our board of directors," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "With over 20 years in the biotech and life science industry, Steve brings a wealth of knowledge and expertise in financial management and corporate s
Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, has appointed Myrtle Potter to serve on its Board of Directors. "We are very pleased to welcome Myrtle Potter to our Board of Directors as we continue to build and deliver on our mission of conquering cancer with data," said Helmy Eltoukhy, Guardant Health Co-CEO and Chairman of the Board. "Myrtle has extensive knowledge and experience bringing world-class therapeutics to market, and her industry expertise will be invaluable as we strive to provide patients across all stages of cancer with access to the latest advancements in precision oncology." "I am thrilled to be joining Guardant Health's Board of Directors at su
SAN MATEO, Calif., Aug. 10, 2021 /PRNewswire/ -- uLab Systems™, creator of uSmile™ clear aligners and uDesign™ treatment planning software, announced today the appointment of three new members to its Board of Directors: Robin Bienfait, AmirAli Talasaz, and Rita O'Connor. uLab Systems announced today the appointment of three new members to its Board of DirectorsRobin Bienfait, CEO for Emnovate, has more than 30 years of experience in mobility, security, business development, enterprise sales, wireless network operations, and engineering. Prior to joining Emnovate, Robin hel
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris Freeman as the company’s new Chief Commercial Officer for its oncology business, effective June 8, 2021. Chris brings significant experience successfully building and managing pharmaceutical and biotechnology brands through all stages of commercialization, which will be invaluable as the company’s oncology portfolio expands to cover advanced and earlier stage cancers. “I am thrilled to welcome Chris Freeman as our new Chief Commercial Officer. Chris’s broad experience leading blockbuster products through commercialization will b
Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excluding Shield) and 10,500 biopharma tests in the third quarter of 2024, representing increases of 21% and 40%, respectively, over the third quarter of 2023 Achieved Guardant360 ASP of over $3,000 Rai
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, G
Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC screening and is commercially available in U.S. Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $177.2 million for the second quarter of 2024, an increase of 29% over the second quarter of 2023 Reported 49,400 tests to clinical customers and 10,475 tests to biopharmaceutical customers in the second quarter of 2024, representing increases of 14% and 56%, respectively, over the second quarte
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates Guardant Health to host investor conference call and webcast Monday, July 29, at 8:30 a.m. ET / 5:30 a.m. PT Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company's Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. It is the
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012,
Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $168.5 million for the first quarter of 2024, an increase of 31% over the first quarter of 2023 Reported 46,900 tests to clinical customers and 8,450 tests to biopharmaceutical customers in the first quarter of 2024, representing increases of 20% and 37%, respectively, over the first quarter of 2023 Reduced free cash flow to $(37.2) million in the first quarter of 2024, compared to $(82.0)
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guar
Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue of $155.1 million for the fourth quarter of 2023, an increase of 22% over the fourth quarter of 2022 Reported 46,400 tests to clinical customers and 9,500 tests to biopharmaceutical customers in the fourth quarter of 2023, representing increases of 29% and 16%, respectively, over the fourth quarter of 2022 Full Year 2023
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.
Q3 revenue increased 22% year over year driven by clinical volume growth of 35% Raises 2023 revenue guidance to $553 to 556 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights Revenue of $143.0 million for the third quarter of 2023, an increase of 22% over the third quarter of 2022 Reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in the third quarter of 2023, representing increas